Q4 and Full-Year 2023 Financial Results of 45 Leading Pharmaceutical Companies Including Pfizer, Johnson & Johnson, Roche, Eli Lilly, Novo Nordisk, and Takeda

Apr 28, 2024 13:18 CST Updated Apr 27, 14:18

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

Pfizer

Pharmaceutical R&D Developer

AbbVie

Innovative Drug Developer

MSD

Pharmaceutical R&D and Manufacturer

Bristol-Myers Squibb

Biopharmaceutical and Nutritional Product R&D and Sales

Eli Lilly

Global Pharmaceutical R&D and Production Company

Amgen

Developer of Treatment Drugs for Serious Diseases

Gilead Sciences

Antiviral Drug Developer

Viatris

Generic Drug Manufacturer

Regeneron

Biopharmaceutical Manufacturer

Biogen

New Drug Developer

Vertex

Breakthrough Small Molecule Drug Developer

Moderna

mRNA Therapeutics Developer

Organon

New Drug Research and Development, Manufacturer

AstraZeneca

Biopharmaceutical Manufacturer

Abbott

Diagnostic and pharmaceutical product manufacturers

Roche

Oncology Drug Research, Development, and Manufacturing

Novartis

Drug Development and Manufacturing

Sanofi

Pharmaceutical R&D Developer

GSK

Pharmaceutical R&D Manufacturer

Novo Nordisk

Insulin Developer and Manufacturer

Boehringer Ingelheim

Developer of Innovative Drugs and Therapies

Bayer

Pharmaceutical Product R&D Developer

Merck Group

Pharmaceutical R&D Developer

Sandoz

Global Supplier of Novel Patent Medicines

Fresenius Medical Care

Dialysis treatment services and dialysis product suppliers

Grifols

Plasma-Derived and Transfusion Medicine Products Manufacturer

UCB

Biopharmaceutical and Specialty Chemicals Developer

BioNTech

Developer of Novel Biologics

Takeda

Biopharmaceutical Manufacturer

CSL

Biological Therapy and Influenza Vaccine Developer

Teva

Drug Developer

Astellas

Pharmaceutical R&D Manufacturer

Daiichi-Sankyo

Pharmaceutical R&D Developer

Otsuka

Drug Developer

Eisai

Pharmaceutical Product R&D and Manufacturer

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

Fosun Pharmaceutical

Healthcare Industry Group

Sino Biopharm

Pharmaceutical R&D Developer

CSPC

Developer of finished drugs and active pharmaceutical ingredients

SPH

Pharmaceutical R&D and Manufacturing

CR PHARMA COMM

Pharmaceutical Circulation Service Provider

Guangzhou Baiyunshan Pharmaceutical Holdings Company

Integrated Service Provider for Pharmaceuticals and Medical Devices

Note: The fiscal year start dates of major companies differ from the calendar year, leading to inconsistencies between fiscal quarters, years, and the natural year.

United States

AbbVie Reports Q4 and Full-Year 2023 Financial Results. Q4 net revenue was $14.3 billion, compared to $15.1 billion in the same period last year. Net profit attributable to the company for the quarter was $822 million, versus $2.473 billion in the prior-year period. Full-year 2023 net revenue reached $54.3 billion, down from $58.1 billion in 2022. Net profit attributable to the company for the full year was $4.863 billion, compared to $11.836 billion in the previous year.

Pfizer Announces Q4 and Full-Year 2023 Financial ResultsPfizer reported its financial results for the fourth quarter and full year of 2023. Revenue for the fourth quarter was $14.249 billion, compared to $24.29 billion in the same period last year, representing a year-over-year decrease of 41%. The company recorded a net loss of $3.37 billion for the quarter, compared to a net profit of $5 billion in the same period last year. For the full year 2023, revenue amounted to $58.5 billion, down from $100.3 billion in 2022, marking a 42% decline. Net profit for the full year was $2.12 billion, significantly lower than $31.37 billion in 2022, reflecting a 93% year-over-year drop.

Johnson & Johnson announced its financial results for the fourth quarter of 2023. Quarterly sales were $21.4 billion, an increase of 7.3% year-over-year. Net profit was $4.13 billion, compared to $3.23 billion in the same period last year. By business segment, excluding COVID-19 vaccine sales, pharmaceutical business revenue reached $13.68 billion. Johnson & Johnson's medical device business sales were $7.67 billion, a year-over-year increase of 13.3%.

Merck & Co., Inc. Announces Q4 and Full-Year 2023 Financial ResultsIn Q4, sales reached $14.63 billion, compared to $13.83 billion in the same period last year, representing a 6% increase. The company reported a net loss of $1.226 billion for the quarter, compared to a net profit of $3.017 billion in the same period last year. Pharmaceutical business sales amounted to $13.141 billion, an 8% increase year-over-year. Animal health business sales reached $1.278 billion, growing by 4%. For the full year, total sales were $60.015 billion, compared to $59.283 billion in the previous year. The company's net profit for the full year was $365 million, compared to $1.4519 billion in the prior year.

Bristol-Myers Squibb announced its financial results for the fourth quarter and full year of 2023. Total revenue for the fourth quarter was $11.477 billion, compared to $11.406 billion in the same period last year. Net income attributable to the company for the quarter was $1.762 billion, compared to a net profit of $2.022 billion in the same period last year. Total revenue for the full year was $45 billion, down from $46.2 billion the previous year. Net income attributable to the company for the full year was $8.025 billion, up from $6.327 billion the previous year.

Eli Lilly Releases Q4 2023 Financial Report: Total Quarterly Revenue Reaches $9.35 Billion, Up 28% Year-over-Year; Net Profit at $2.19 Billion Compared to $1.94 Billion in the Same Period Last Year

Amgen Inc. Announces Q4 and Full-Year 2023 Financial Results. Total revenue for Q4 was $8.196 billion, compared to $6.839 billion in the same period last year. Quarterly net profit was $767 million, compared to $1.616 billion in the same period last year, representing a year-over-year increase of 52%. Total revenue for 2023 was $28.19 billion, compared to $26.323 billion in 2022. Full-year net profit was $6.717 billion, compared to $6.552 billion in the previous year.

Gilead Sciences Announces Q4 and Full-Year 2023 Financial ResultsGilead Sciences announced its financial results for the fourth quarter and full year of 2023. Total revenue for the fourth quarter was $7.115 billion, compared to $7.389 billion in the same period last year. Net income attributable to the company for the quarter was $1.429 billion, compared to $1.64 billion in the prior-year period. For the full year, total revenue amounted to $27.116 billion, versus $27.281 billion in the previous year. The net income attributable to the company for the full year was $5.665 billion, compared to $4.592 billion in the prior year.

Viatris Announces Q4 and Full-Year 2023 Financial Results. Total revenue for the fourth quarter was $3.837 billion, compared to $3.876 billion in the same period last year. The net loss for the quarter was $766 million, while the net profit for the same period last year was $1.011 billion. Total revenue for the full year was $15.427 billion, down from $16.263 billion the previous year. Net profit for the full year was $54.7 million, compared to $2.079 billion the previous year.

Regeneron Pharmaceuticals, Inc. Announces Q4 and Full-Year 2023 Financial ResultsTotal revenue for the fourth quarter was $3.434 billion, compared to $3.414 billion in the same period last year. Quarterly net income was $1.16 billion, compared to $1.197 billion in the prior-year period. For the full year, total revenue reached $13.117 billion, up from $12.173 billion the previous year. Full-year net income was $3.954 billion, compared to $4.338 billion in the prior year.

Biogen Reports Q4 and Full-Year 2023 Financial Results. Total revenue for the fourth quarter was $2.386 billion, compared to $2.544 billion in the same period last year. Net income attributable to the company for the quarter was $250 million, versus $550 million in the prior-year period. For the full year, total revenue reached $9.836 billion, down from $10.173 billion the previous year. Full-year net income attributable to the company was $1.16 billion, compared to $3.05 billion in the prior year.

Vertex Pharmaceuticals Announces Q4 and Full-Year 2023 Financial ResultsQ4 net product revenue reached $2.518 billion, compared to $2.303 billion in the same period last year. Quarterly net profit was $969 million, up from $819 million in the prior-year quarter. Full-year net product revenue amounted to $9.869 billion, versus $8.931 billion the previous year. Annual net profit totaled $3.62 billion, an increase from $3.32 billion in the prior year.

Moderna Announces Q4 and Full-Year 2023 Financial Results. Total revenue for the fourth quarter was $2.811 billion, compared to $5.084 billion in the same period last year. Quarterly net income was $217 million, compared to $1.465 billion in the prior-year quarter. Full-year revenue was $6.848 billion, down from $19.263 billion the previous year. The annual net loss was $4.714 billion, compared to a net profit of $8.362 billion in the prior year.

Organon Announces Q4 and Full-Year 2023 Financial ResultsOrganon reported its financial results for the fourth quarter and full year of 2023. Revenue for the fourth quarter was $1.598 billion, compared to $1.485 billion in the same period last year. Quarterly net profit reached $546 million, up from $108 million in the prior-year quarter. For the full year, revenue amounted to $6.263 billion, versus $6.174 billion in the previous year. The annual net profit was $1.023 billion, an increase from $917 million in the prior year.

Abbott Reports Q4 2023 Earnings. Quarterly revenue increased by 1.5% year-over-year to $10.24 billion. By segment, revenue from the medical devices division was $4.44 billion, up 17.5% year-over-year. Nutrition business revenue reached $2.04 billion, a 12% increase year-over-year. Diagnostics business revenue was $2.53 billion, down 23% year-over-year. Generic drug business sales amounted to $1.22 billion, a 0.5% increase year-over-year. Quarterly net profit was $1.594 billion, compared to $1.033 billion in the same period last year.

Europe

Roche Announces Financial Results for 2023. Total Group Sales for the Year Amounted to CHF 58.716 Billion, Compared to CHF 63.281 Billion in the Previous Year. Pharmaceutical Business Sales Reached CHF 44.612 Billion (Approximately USD 48.9 Billion), with Operating Profit at CHF 17.132 Billion. Diagnostics Business Sales Were CHF 14.104 Billion, with Operating Profit at CHF 2.171 Billion. Net Profit Attributable to Shareholders of the Company for the Full Year Was CHF 11.498 Billion, Compared to CHF 12.421 Billion in the Same Period Last Year.

AstraZeneca announced its financial results for the fourth quarter and full year of 2023. The revenue for the fourth quarter was $12.024 billion, compared to $11.207 billion in the same period last year. The post-tax profit for the quarter was $959 million, compared to $902 million in the same period last year. The total revenue for the full year was $45.811 billion, compared to $44.351 billion last year. The post-tax profit for the full year was $5.961 billion, compared to $3.293 billion last year.

Novartis Reports Q4 and Full-Year 2023 Financial Results. Q4 net sales were $11.423 billion, up 8% year-over-year; quarterly net income was $2.638 billion, up 101% year-over-year. Full-year net sales reached $45.4 billion, up 10% year-over-year. Net sales in China amounted to $3.3 billion, up 17% year-over-year.

Sanofi announced its financial results for the fourth quarter and full year of 2023. Total revenue in the fourth quarter reached €10.9 billion, representing a year-over-year increase of 9.3%. Full-year sales amounted to €43.07 billion, marking a 5.3% increase compared to the previous year. Specifically, pharmaceutical business revenue was €30.4 billion (approximately $32.3 billion), vaccine business revenue totaled €7.5 billion (approximately $7.96 billion), and consumer healthcare business revenue reached €5.2 billion.

GSK Releases Q4 and Full-Year 2023 Financial Results. Q4 revenue reached £8.052 billion (approximately $10 billion), compared to £7.376 billion in the same period last year. Operating profit for the quarter was £573 million, down from £1.868 billion in the previous year. Net profit attributable to shareholders from continuing operations was £350 million, compared to £1.5 billion in the same period last year. Full-year revenue amounted to £30.328 billion (approximately $37.7 billion), up from £29.324 billion the previous year. Annual operating profit was £6.745 billion, compared to £6.433 billion the previous year. Net profit attributable to shareholders from continuing operations for the full year was £4.928 billion, up from £4.461 billion the previous year.

Novo Nordisk Reports 2023 Financial Results. Full-year operating profit grew by 37% in Danish kroner to DKK 102.6 billion, or 44% at constant exchange rates. Sales increased by 31% to DKK 232.3 billion (approximately USD 33.1 billion), or 36% at constant exchange rates. Semaglutide, Novo Nordisk's flagship product, generated DKK 145.811 billion in revenue in 2023.

Boehringer Ingelheim Releases Full-Year 2023 Performance. In 2023, the group's total revenue increased by 9.7% year-over-year to EUR 25.611 billion. Of this, human pharmaceuticals revenue totaled EUR 20.774 billion (approximately USD 22.1 billion), representing a year-over-year increase of 10.3%. Revenue from the animal health business reached EUR 4.724 billion, growing by 6.9%. The company’s full-year R&D investment increased by 14.2% year-over-year to EUR 5.8 billion, accounting for 22.5% of total revenue.

Bayer Group Announces Q4 and Full-Year 2023 Financial ResultsBayer Group announced its financial results for the fourth quarter and full year of 2023. In the fourth quarter, the group's sales revenue was €11.862 billion, compared to €12 billion in the same period last year. Quarterly net profit reached €1.337 billion, up from €611 million in the same period last year. By business segment, Crop Science division reported sales of €5.63 billion with EBIT profit of €975 million. Pharmaceuticals division achieved sales of €4.579 billion (approximately $4.86 billion) with EBIT profit of €935 million. Consumer Health division recorded sales of €1.578 billion with EBIT profit of €424 million. For the full year, the group’s total sales revenue amounted to €47.637 billion, down from €50.739 billion in the previous year. The net loss attributable to shareholders of the company for the full year was €2.941 billion, compared to a net profit of €4.15 billion in the previous year.

German pharmaceutical and chemical giant Merck Group announced its Q4 and full-year 2023 financial results. In Q4, net sales were €5.225 billion, compared to €5.66 billion in the same period last year. Specifically, Life Science business net sales reached €2.249 billion (approximately $2.388 billion), Healthcare business net sales amounted to €2.032 billion (approximately $2.157 billion), and Electronics Technology business net sales were €943 million. For the full year, net sales totaled €20.993 billion, down from €22.232 billion the previous year. Full-year EBITDA profit was €5.489 billion, compared to €6.504 billion the previous year. Net profit after tax for the full year was €2.834 billion, down from €3.339 billion the previous year.

Sandoz Announces Q4 and Full-Year 2023 Results. Q4 Sales Reach $2.543 Billion, Compared to $2.296 Billion in the Same Period Last Year. Full-Year Sales Amount to $9.647 Billion, Up from $9.069 Billion the Previous Year. Full-Year EBITDA Profit Totals $914 Million, Down from $1.741 Billion the Prior Year.

Fresenius Group Announces Q4 and Full-Year 2023 Financial ResultsFresenius Group (FRESENIUS GROUP) reported its financial results for the fourth quarter and full year of 2023. In Q4, the group generated revenue of €5.678 billion, EBITDA of €942 million, and net profit of €397 million. Fresenius Kabi reported revenue of €1.996 billion (approximately $2.12 billion), compared to €2.036 billion in the same period last year. Fresenius Helios Clinics achieved revenue of €3.188 billion, up from €3.031 billion in the previous year. For the full year, the group’s revenue reached €22.299 billion, with EBITDA at €3.422 billion and net profit at €1.505 billion.

Grifols Announces Q4 and Full-Year 2023 Financial ResultsQ4 Revenue: €1.77 billion (approximately $1.88 billion), compared to €1.71 billion in the same period last year. Q4 EBIT: €255 million, with profit from continuing operations at €77.73 million. Full-year revenue: €6.59 billion (approximately $7 billion), compared to €6.06 billion last year. Full-year EBIT: €799 million, with profit from continuing operations at €181 million.

UCB Announces 2023 Financial Results. Full-year revenue reached €5.252 billion (approximately $5.58 billion), compared to €5.517 billion in the previous year. Adjusted EBITDA for the full year was €1.349 billion, versus €1.26 billion in the prior year. Net profit attributable to shareholders of the company for the full year was €343 million, compared to €418 million in the previous year.

BioNTech Announces Q4 and Full-Year 2023 Financial Results. Total revenue for Q4 was €1.479 billion (approximately $1.57 billion), compared to €4.278 billion in the same period last year. Quarterly net profit was €458 million, compared to €2.279 billion in the prior-year quarter. Full-year total revenue amounted to €3.819 billion (approximately $4.055 billion), down from €17.311 billion the previous year. Annual net profit was €930 million, compared to €9.434 billion the previous year.

Ipsen Announces Full-Year 2023 Financial ResultsIpsen, a biopharmaceutical company, reported its full-year 2023 financial results. Total sales for the year reached €3.128 billion (approximately $3.32 billion), compared to €3.025 billion in the previous year. Core operating profit for the year was €1 billion, down from €1.115 billion the previous year. Core consolidated net profit for the year amounted to €766 million, compared to €872 million in the prior year.

Asia-Pacific

Takeda Pharmaceutical Company Limited Reports Financial Results for the First Nine Months (April-December) of the Fiscal Year Ending December 31, 2023. Revenue for the period was 3,212.9 billion yen (approximately 20.8 billion USD), compared to 3,071.3 billion yen in the same period last year, representing a 4.6% increase year-over-year. Operating profit for the period was 224.1 billion yen, down 44.2% from 401.9 billion yen in the same period last year. Net profit attributable to owners of the company for the period was 147.1 billion yen, a decrease of 48.6% compared to 285.9 billion yen in the same period last year.

CSL Group Announces Financial Results for the First Half of Fiscal Year Ending December 31, 2023Australian biopharmaceutical company CSL Group announced its financial results for the first half of the fiscal year ending December 31, 2023. During this period, the group's total revenue was $8.053 billion, compared to $7.184 billion in the same period last year. Operating profit for the period was $3.787 billion, compared to $3.359 billion in the same period last year. Net profit attributable to the company for the period was $2.017 billion, compared to $1.818 billion in the same period last year. Among these, CSL Behring's revenue was $5.238 billion, CSL Seqirus' revenue was $1.804 billion, and CSL Vifor's revenue was $1.011 billion.

Teva Pharmaceutical Industries announced its financial results for the fourth quarter and full year of 2023. Net revenue for the fourth quarter was $4.457 billion, compared to $3.884 billion in the same period last year. Net profit attributable to the company for the quarter was $461 million, compared to a net loss of $1.3 billion in the same period last year. Full-year net revenue was $15.846 billion, compared to $14.925 billion the previous year. Full-year net loss attributable to the company was $559 million, compared to a net loss of $2.446 billion the previous year.

Astellas Pharma Inc. Announces Financial Results for the First Nine Months (April-December) of the Fiscal Year Ending December 31, 2023Revenue for the period was 1,189.1 billion yen (approximately 7.7 billion USD), compared to 1,164.3 billion yen in the same period last year, representing a 2.1% year-over-year increase. Operating profit for the period was 149.6 billion yen, down 36% from 233.7 billion yen in the same period last year. Net profit for the period was 120.5 billion yen, a decrease of 36.2% compared to 188.9 billion yen in the same period last year.

Daiichi Sankyo Company, Limited announced its financial results for the first nine months (April-December) of the fiscal year ending December 31, 2023. Revenue for the period reached 1,173.3 billion yen (approximately 7.6 billion US dollars), compared to 948.3 billion yen in the same period last year, representing a year-on-year increase of 23.7%. Operating profit for the period was 194.6 billion yen, up from 127.1 billion yen in the previous year, marking a 53% growth. Net profit attributable to the company's owners was 163.6 billion yen, compared to 86.7 billion yen in the same period last year, reflecting an 88.7% increase.

Otsuka Holdings Co., Ltd. Announces Financial Results for 2023. Total annual revenue reached 2,018.6 billion yen, compared to 1,738.0 billion yen in the previous year. Annual operating profit was 139.6 billion yen, compared to 150.3 billion yen in the previous year. Net profit attributable to the company's owners for the full year was 121.6 billion yen, compared to 133.9 billion yen in the previous year. Among this, pharmaceutical business revenue was 1,364.3 billion yen (approximately 8.83 billion USD), nutrition business revenue was 483.7 billion yen, and consumer goods business revenue was 37.1 billion yen.

Eisai Co., Ltd. Announces Financial Results for the First Nine Months (April-December) of the Fiscal Year Ending December 31, 2023. Revenue for the period was 551.3 billion yen (approximately 3.57 billion USD), compared to 546.2 billion yen in the same period last year, representing a year-on-year increase of 0.9%. Operating profit for the period was 37.537 billion yen, compared to 13.823 billion yen in the same period last year, reflecting a year-on-year increase of 172%. Net profit attributable to owners of the parent company for the period was 29.1 billion yen, compared to 39.1 billion yen in the same period last year, representing a year-on-year decrease of 25.6%.

China

Hengrui Pharma Releases 2023 Annual Report. The company achieved operating revenue of 22.82 billion yuan, a year-on-year increase of 7.26%, with a net profit attributable to shareholders of the listed company at 4.302 billion yuan, up 10.14% year-on-year, and a non-recurring net profit attributable to shareholders of the listed company at 4.141 billion yuan, increasing by 21.46% year-on-year. In 2023, the company's innovative drug revenue reached 10.637 billion yuan (including tax, excluding external licensing revenue). Despite challenges such as changes in the external environment, product price reductions, and market access difficulties, it still achieved a year-on-year growth of 22.1%.

Hansoh Pharma Releases 2023 Annual Performance Report

Fosun Pharmaceutical Releases 2023 Annual Report. Total revenue for the year reached 41.4 billion yuan, a year-on-year decrease of 5.81%; net profit attributable to shareholders of the listed company was 2.386 billion yuan, a year-on-year decrease of 36.04%. In 2023, Fosun Pharmaceutical's pharmaceutical business achieved revenue of 30.222 billion yuan, its medical devices and medical diagnostics business achieved revenue of 4.39 billion yuan, and its healthcare services business achieved revenue of 6.672 billion yuan, a year-on-year increase of 9.74%.

Sino Biopharm Releases 2023 Annual Results: Full-Year Revenue of RMB 26.2 Billion, Up 0.7% Year-on-Year; Adjusted Net Profit Attributable to Shareholders at RMB 2.59 Billion, Up 1.5% Year-on-Year; Innovative Product Revenue Reaches RMB 9.89 Billion, Increasing by 13.3% Year-on-Year; R&D Investment in 2023 at RMB 4.4 Billion, Accounting for 16.8%.

CSPC Pharmaceutical Group Limited Discloses Full-Year 2023 Performance. The company achieved revenue of 31.45 billion yuan, a year-on-year increase of 1.7%; net profit was 5.87 billion yuan, a year-on-year decrease of 3.6%. Among this, the finished drug business achieved revenue of 25.637 billion yuan, a year-on-year increase of 4.6%, while raw material products, functional foods, and others achieved revenues of 3.641 billion yuan and 2.172 billion yuan respectively, with year-on-year decreases of 9.7% and 8.9% respectively.

SPH Releases 2023 Annual Report. In 2023, the company achieved a revenue of 260.295 billion yuan, representing a year-on-year increase of 12.21%. Of this, the pharmaceuticals industry generated sales revenue of 26.257 billion yuan, marking a year-on-year decrease of 1.87%, while the pharmaceuticals commerce segment achieved sales revenue of 234.038 billion yuan, reflecting a year-on-year growth of 14.04%. Due to the impact of one-time gains and losses, net profit attributable to shareholders was 3.768 billion yuan, down 32.92% year-on-year. Excluding the impact of one-time gains and losses, net profit attributable to shareholders amounted to 4.919 billion yuan, up 2.99% year-on-year.

CR PHARMA COMM Announces 2023 Financial Results. Revenue reached RMB 244.7 billion in 2023, compared to RMB 218.2 billion in 2022. Profit attributable to equity holders of the company was RMB 3.854 billion, up from RMB 3.5 billion the previous year. During the reporting period, the Traditional Chinese Medicine (TCM) business segment generated revenue of RMB 21.593 billion; the chemical pharmaceuticals business achieved revenue of RMB 17.032 billion; biopharmaceuticals generated revenue of RMB 2.136 billion; and nutrition, health products, and other businesses contributed revenue of RMB 2.704 billion. The Group's pharmaceutical distribution business achieved segment revenue of RMB 202.3 billion, representing a year-on-year increase of 11.4%. Pharmaceutical retail operations recorded revenue of RMB 9.578 billion, reflecting a year-on-year growth of 26.2%.

Guangzhou Baiyunshan Pharmaceutical Holdings Company (Guangzhou Pharmaceuticals) Discloses Q4 and Full-Year 2023 Financial Results. Q4 revenue reached 17.33 billion yuan, with a net profit attributable to shareholders of 264 million yuan. Full-year revenue amounted to 75.515 billion yuan, representing a 6.68% increase over the previous year. The full-year net profit attributable to shareholders was 4.056 billion yuan, up 2.25% year-on-year. Of this, traditional Chinese medicine business revenue was 6.27 billion yuan, while chemical pharmaceuticals revenue was 4.618 billion yuan.

Scan the WeChat QR code to add.Medicine Space-TimeEditor

Please indicate: Name + Research Direction!